Gary Patou

Executive Partner at Mpm Capital LLC

Gary Patou

Gary Patou

Executive Partner at Mpm Capital LLC

Overview
Career Highlights

Genesoft Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc.

RelSci Relationships

2818

Number of Boards

3

Birthday

1959

Age

61

Relationships
RelSci Relationships are individuals Gary Patou likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at MPM Asset Management LLC

Relationship likelihood: Strong

Co-Founder at Mpm Capital LLC

Relationship likelihood: Strong

Co-Founder at Xenon Pharmaceuticals, Inc.

Relationship likelihood: Strong

Former Chief Executive Officer at Xenon Pharmaceuticals, Inc.

Relationship likelihood: Strong

President, Chief Financial Officer & Secretary at Xenon Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chairman, Chief Executive & Operating Officer at Pacira Biosciences, Inc.

Relationship likelihood: Strong

President & Chief Financial Officer at Chiasma, Inc.

Relationship likelihood: Strong

General Counsel & Chief Compliance Officer at MPM Oncology Impact Management LP

Relationship likelihood: Strong

Co-Founder at Cullinan Oncology LLC

Relationship likelihood: Strong

Chief Executive Officer at Chiasma, Inc.

Relationship likelihood: Strong

Paths to Gary Patou
Potential Connections via
Relationship Science
You
Gary Patou
Executive Partner at Mpm Capital LLC
Education
MD Unknown

University College London (UCL) is a public research university in London, England, and the oldest and largest constituent college of the federal University of London. Founded in 1826 as London University, UCL was the first university institution established in London and the first in England to be entirely secular, to admit students regardless of their religion, and to admit women on equal terms with men. The philosopher Jeremy Bentham is commonly regarded as the spiritual father of UCL, as his radical ideas on education and society were the inspiration to its founders, although his direct involvement in its foundation was limited. UCL became one of the two founding colleges of the University of London in 1836. It has grown through mergers, including with the Institute of Neurology (in 1997), the Royal Free Hospital Medical School (in 1998), the Eastman Dental Institute (in 1999), the School of Slavonic and East European Studies (in 1999) and the School of Pharmacy (in 2012). UCL's main campus is located in the Bloomsbury area of central London, with a number of institutes and teaching hospitals located elsewhere in central London, and satellite campuses in Adelaide, Australia and Doha, Qatar. UCL is organised into 10 constituent faculties, within which there are over 100 departments, institutes and research centres. UCL has around 26,700 students and 11,025 staff and had a total income of £937 million in 2012/13, of which £335 million was from research grants and contracts. UCL has around 4,000 academic and research staff and 650 full professors, the highest number of any British university. UCL is responsible for several museums and collections in a wide range of fields across the arts and sciences, including the Petrie Museum of Egyptian Archaeology, a leading collection of Egyptian and Sudanese archaeology.

The University of London is a collegiate research university located in London, England, consisting of 18 constituent colleges, 10 research institutes and a number of central bodies. The nine largest institutions of the federal university, usually termed the colleges, are Birkbeck, Goldsmiths, King's College London, the London Business School, Queen Mary, Royal Holloway, SOAS, LSE and UCL. Formerly a constituent college, Imperial College London left the University of London in 2007.

Career History
Head of Clinical
2014 - Current

Chiasma, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The firm's Transient Permeability Enhancer (TPE) technology platform, seeks to develop oral medications. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Waltham, MA.

Executive Partner
2005 - Current

MPM invests in companies located in the US and across the globe. The firm focuses on companies that aim to revolutionize the face of medicine across multiple areas including cancer, diabetes, obesity, pain, eHealth and health technology sector. They provide financing for early stage transactions.

Chief Medical Officer
Current

Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA.

Boards & Committees
Director
1991 - 1995

Vernalis Plc is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of the antibiotic and amoxicillin; and frovatriptan, used for the acute treatment of migraine. Vernalis also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, the United Kingdom.

Transactions
Details Hidden

Blade Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Blade Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Cerimon Pharmaceuticals, Inc. raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Gary Patou. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Gary Patou's profile does not indicate a business or promotional relationship of any kind between RelSci and Gary Patou.